4-FA

Repaired from the refuted NPSG attribution. The current SV expressly names 4-Fluoroamphetamin (4-FA) in Annex IV.1 and equates Annex IV.1 substances with Suchtgifte under SMG § 2(2). The prohibited status therefore rests on the SV/SMG regime: SMG § 27 addresses vorschriftswidrig unauthorized acquisition, possession, production, transport, import/export, offering, transfer and supply, subject to its specific statutory qualifications and penalties. NPSG § 2(2) excludes substances subject to the SMG, so this entry does not characterize 4-FA as controlled under NPSG or assert an unqualified prohibition of every act irrespective of authorization or statutory exception.

Supported current primary-source result for mainland China's national controls. The official Shenzhen Public Security Bureau current controlled-substance portal expressly places 4-FA in section III, the 2025 non-medical narcotic and psychotropic directory, as entry 18, with the exact Chinese and English chemical names and CAS 459-02-9. Under Article 4 of the current national regulation, non-medical listed substances may be used only for legally compliant experimental research and may not be produced, dealt in, used, stored, or transported; this supports the canonical status prohibited, not ordinary prescription-only access. The 2025 medicinal narcotic and psychotropic schedules are separate directories. The directory notes include salts and stereoisomers (and their salts) unless otherwise specified; the entry-specific scope here is therefore the listed 4-FA substance and those expressly covered forms, not unlisted analogues. This result is limited to mainland China's national directories and law available on 2026-08-27.

The current e-Sbírka rendition inspected on 27 August 2026 identifies Regulation No. 463/2013 Coll. as current from 25 June 2026 and displays 4-Fluoramfetamin / 4-FA / 1-(4-fluorfenyl)propan-2-amin in Annex 4, List 4 psychotropic substances. Act No. 167/1998 Coll. defines psychoactive substances listed in Annexes 1 through 7 of the Government Regulation as addictive substances; its handling definition covers research, manufacture, processing, acquisition, storage, supply, use, purchase and sale. For Annex 4 substances, use is limited to the restricted research, scientific and very limited therapeutic purposes defined in a handling permit, and § 4 generally requires a handling permit. The cited provisions do not establish an ordinary prescription-medicine route for 4-FA or enumerate individual permit holders; the prohibited label therefore means unauthorized handling, not that every licensed research or very limited therapeutic activity is impossible. No ordinary consumer, recreational or general commercial exception was located in the inspected operative provisions.

The current consolidated National Legislation Database rendition of Decree 78/2022 inspected on 2026-08-27 is dated 2026.06.29 and expressly places 4-FA in Annex 2, P2. The P2 clause extends each listed substance to qualifying stereoisomers and salts where they exist and are not expressly excepted; the annex says the A-C columns control classification, while formula and InChIKey columns are for computer searching. Btk § 459(1a), as established by the 2025 amendment, defines kábítószer for the relevant offenses to include substances in Annex 2 P1/P2, so the P2 listing is legally operative for the drug offenses. Btk §§ 176 and 178 criminalize offering, transfer, distribution, trade, acquisition, possession, import, export and transit of a kábítószer; § 178(6) separately criminalizes consumption and acquiring/possessing a small quantity for consumption. The current Btk threshold is a maximum 1 gram of pure active 4-fluoroamphetamine calculated in base form under § 461(1)(ah), not a lawful possession allowance. Btk § 180 provides a conditional, fact-specific non-punishment route for certain small-quantity own-use conduct only where all statutory conditions are met (including admission, documented six-month treatment/other care/preventive service and disclosure/cooperation); it does not legalize 4-FA. The activity-control decree requires a permit for listed controlled-substance production, manufacture, export, import, transfer, acquisition, distribution, storage, possession, supply, use, research, analysis and related activities, with a separate case-specific export/import permit for import/export. Medical status is limited and conditional: the medicines act defines a P2-P4 active-ingredient medicine as a psychotropic-classified medicine, while the prescription decree allows a doctor to order an authorized medicine or magistral medicine; P2-classified medicines may only be issued on prescription, and a P2 medicine cannot be dispensed against a foreign prescription covered by the foreign-prescription rule. These provisions do not establish that raw 4-FA is an approved medicine or create ordinary recreational access. Accordingly, prohibited is supported for ordinary unauthorized conduct, while statutory permits and the narrow § 180 conditions remain limitations; this is not an assertion that every act is unlawful regardless of authorization or case-specific defense.

The existing entry is substantively supported but should use the exact Italian schedule designation and identify the 2012 Ministry decree. Article 1 of the decree expressly inserts 4 Fluoroamfetamina in Tabella I and gives the chemical designation ((RS)-1-(4-fluorofenil)propan-2-amina) and other denomination 4-FA; the decree entered into force on the fifteenth day after publication (27 November 2012). The decree's rationale identifies 4-Fluoroamfetamina as an amphetamine analogue and central-nervous-system stimulant. Normattiva's current-date page confirms that the governing D.P.R. 309/1990 remains in force at 27 August 2026 and was last updated 6 August 2026; a 28 April 2026 Ministry update confirms that Table I remains an actively maintained schedule under that decree. This supports canonical prohibited as a Table I scheduling classification, not prescription-only status. Article 73 is the applicable enforcement framework for unauthorized conduct involving Table I substances, while personal-use facts can engage separate provisions; this dossier does not make a fact-specific determination about personal-use administrative treatment, research authorization, medical supply, penalties under every temporal version, or a particular preparation beyond the statutory inclusion rules.

Current-law supported correction. The authoritative Swiss schedule expressly lists 4-Fluoroamphetamin (4-FA) and 1-(4-Fluorophenyl)propan-2-amin under the d designation in Annex 5 (Verzeichnis d), with GTIN 7611746991052. BetmKV defines Verzeichnis d as prohibited controlled substances. This is a prohibition/control classification, not an ordinary prescription or pharmacy dispensing classification: the schedule does not itself create a medical authorization, and the inspected rules provide only the applicable permit/exception routes. Unauthorized possession, custody, acquisition, production, import/export, sale or other handling can trigger BetmG controls and offences; licensed handling and statutory BAG exceptions remain relevant. BetmVV-EDI Article 1(2) extends control to the listed substance's specified salts, esters, ethers, carbamates, stereoisomers, certain derivatives of those stereoisomers and preparations containing covered substances; no broad rule for unrelated analogues was inferred. The directly readable BetmKV consolidation used for the category and permit wording is dated 1 January 2022, while the current Fedlex instrument page was inspected but rendered only a JavaScript availability notice. Swissmedic says its supplementary lists are not exhaustive and that only the BetmVV-EDI schedules are binding. This is a research snapshot as of 27 August 2026, not legal advice.

The current Belgian framework is a national generic structural schedule. AFMPS's current legislation page (last updated 16 July 2026) identifies the 6 September 2017 Royal Decree as the governing instrument and warns that only Official Gazette annexes and amendments have official legal value; its consolidated Annex IV PDF is expressly a non-official aid and says Annex IVa cannot be rendered as a limitative named list. Under Article 6 of the decree, import, export, transport, manufacture, production, possession, sale, offering for sale, supply, delivery and acquisition of listed products require prior activity authorization; that authorization is personal and limited to scientific or medical purposes. Article 21 requires a legally obtained signed and dated medical prescription for pharmacy delivery of medicines to the public and adds address, dose, unit-count, dosage and (where applicable) duration requirements for Annex IV substances; this regulates a medicine-delivery pathway and does not establish an approved 4-FA medicine or ordinary recreational legality. Article 61 applies the Article 2bis drug-law penalties to decree violations (the cannabis-only lower-penalty exceptions do not apply to 4-FA). As of 27 August 2026, the operative pre-reform Article 2bis text provides imprisonment of three months to five years and a EUR 1,000-100,000 fine for ordinary intentional violations, with higher reclusion ranges for specified aggravating circumstances; the 16 March 2026 penalty-reform language is annotated as effective 1 September 2026 and is not treated as current on the access date. Article 63 also requires a physician or dentist who prescribed or obtained products to justify their use when required before the Federal Commission for the Control of Healthcare Practice. No ordinary prescription authorization for 4-FA itself was established.

The packet's generic Controlled status is supported and should be corrected to canonicalStatus prohibited. The official Bulgarian List I schedule expressly names 4-FA; the systematic-name parenthesis anomaly is reproduced exactly as printed in the State Gazette. List I is defined as high-risk substances prohibited for application in human and veterinary medicine. Under the Control of Narcotic Substances and Precursors Act, Article 30 prohibits production, processing, trade, storage, import, export, re-export, transit, carrying, transport, offering, acquisition, use and possession of List I plants, narcotic substances and preparations. Article 4(2) applies the same control measures to preparations and analogues. Article 31 and Article 73 preserve only tightly limited, permit-based quantities and activities for medical, scientific, laboratory-research and educational purposes (and service-dog training); these exceptions do not create ordinary medical or prescription access to 4-FA. The latest State Gazette amendment inspected (Decree No. 100/2026, published 14 August 2026) changes specifically enumerated List I rows and does not identify 4-FA as changed; the 4-FA List I entry is also reproduced in the official 2023 List I price schedule. This supports treating the 4-FA List I classification as current on 2026-08-27, while avoiding an unqualified claim that every possible act is unlawful regardless of statutory authorization.

Current official Ley Chile text places the exact identity 1-(4-fluorofenil)propan-2-amina (4-FA) in Article 1 of Decreto 867. Article 1 is the severe-effects category referred to by Article 1 of Law 20.000, not the lower Article 2 category. Law 20.000 Articles 1 and 3 make unauthorized manufacture, trafficking, import, export, transport, acquisition, transfer, possession, supply, keeping or carrying of Article 1 substances criminal; Article 4 provides only a limited small-quantity treatment/personal-exclusive-and-proximate-use justification, not general legalization. Article 6 penalizes a physician, dentist or veterinarian who prescribes an Article 1 substance without medical or therapeutic need. The current Decreto 405 psychotropic-regulation text (latest version 4 June 2025) was inspected as a medicinal-list cross-check and contains no 4-FA occurrence in its Lists I-IV; this is not a product-registration search. No ordinary prescription pathway for 4-FA was established. The Decreto 867 consolidated text extends its Article 1 listings to isomers, esters and ethers (unless expressly excepted) and salts (including salts of those forms), but does not establish a blanket rule for every analogue outside those categories.

The current 2023 list superseded the NN 13/19 and 134/21 list on 18 February 2023. The latest located official list amendment, NN 154/2024, adds O-PCE and changes precursor entries; it does not amend the amphetamines row. The 2009 official list expressly named parafluoramfetamin / Parafluoroamphetamine as 1-(4-fluorfenil)propan-2-amin (1-(4-fluorophenyl)propan-2-amine), corroborating the identity and historical Croatian treatment, but that list is historical and was superseded. The statutory exception is conditional and does not establish that 4-FA is an approved medicine or generally prescription-available; no official source inspected identified a 4-FA medicinal product or prescription authorization. Article 190(2)'s current maximum for unauthorized production, processing, import or export is three years after the 2025 amendment.

The current consolidated First Schedule expressly names פלואורואמפטאמין / Fluoroamphetamine, gives FMP as a synonym, and covers the ortho, meta, or para position. WHO identifies 4-FA as 1-(4-fluorophenyl)propan-2-amine, so 4-FA is the para member of the Israeli entry. Under section 1, a dangerous drug includes a substance in the First Schedule and its salts, preparations, compounds, mixtures, solutions, and their salts. Section 7 prohibits possession and use unless permitted by the Ordinance, regulations, or a Director's licence; section 13 similarly prohibits import, export, trade, other transactions, and supply absent a statutory, regulatory, or licensed authorization. The ordinary Personal Import Order expressly does not apply to dangerous drugs under section 7(1), so it does not create a personal-import exemption. The listing is in Part A, not Part B; section 11's specified possession route for drugs in Part B therefore is not an ordinary prescription classification for 4-FA. No 4-FA-specific medical authorization or prescription status is established by the inspected sources. The prior article's December 2007 date is not relied upon; the current consolidated entry bears amendment references to Gazette amendments from 2008 and 2010, and the latest inspected 2025 First-Schedule notice adds other substances rather than replacing this current entry. Canonical status is prohibited for ordinary unauthorized possession/use and commerce, subject to any authorization expressly available under Israeli law.

The official Turkish National Police Narkotics archive's Turkish EMCDDA report identifies 4-FA as '4-FA (4-floroamfetamin)', establishing the substance identity used here. The current Justice Ministry consolidated Penal Code text criminalizes unlicensed manufacture, import/export, domestic sale, offering, giving, dispatch, transport, storage, purchase, acceptance and possession of uyuşturucu veya uyarıcı maddeler in Article 188(1) and (3). Article 188(4)(a) expressly includes 'amfetamin ve türevleri' and raises the penalty by one half; Law No. 7445 Article 17 inserted that phrase, effective on publication on 5 April 2023. Article 191(1) separately criminalizes purchasing, accepting, possessing for use, or using a narcotic or stimulant substance. Article 188(6) extends the preceding rules to any substance producing a narcotic or stimulant effect whose production requires official authorization or whose sale requires an authorized doctor's prescription. No inspected official Turkish source provided a separate approved-medicine or ordinary prescription route for raw 4-FA; this dossier therefore does not assert medical availability. The official sources inspected did not provide a current Turkish schedule row naming 4-FA verbatim; the supported classification is the statutory amphetamine-derivative category, not a claim that the 2011 named-substance decision expressly listed 4-FA. Application to a particular sample remains dependent on forensic identity and the facts of the conduct, and lawful authorization or case-specific statutory treatment provisions are not ruled out.